Charcot-Marie-Tooth Disease
Pharnext CMT drug shows positive Phase III results
April 29, 2021CMT, Charcot-Marie-Tooth Disease, Phase III trial, pharma, pharma news, pharnext
Pharnext SA’s PXT3003 treatment for patients with Charcot-Marie-Tooth Disease (CMT) has shown positive interim results in its ongoing Phase III …
Latest content
MedPharm appoints Jason Mieding as chief operating officer
November 8, 2026
Coriolis Pharma appoints Teun van der Heide as CEO
November 7, 2026
